Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson Sells 1,000 Shares

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $21.27, for a total transaction of $21,270.00. Following the completion of the transaction, the vice president now owns 2,368 shares of the company’s stock, valued at $50,367.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, August 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $21.10, for a total transaction of $21,100.00.
  • On Friday, August 9th, Brent Johnson sold 2,400 shares of Iradimed stock. The shares were sold at an average price of $21.81, for a total transaction of $52,344.00.
  • On Monday, August 5th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $21.94, for a total transaction of $65,820.00.
  • On Wednesday, August 7th, Brent Johnson sold 7,000 shares of Iradimed stock. The shares were sold at an average price of $21.93, for a total transaction of $153,510.00.
  • On Friday, August 2nd, Brent Johnson sold 5,000 shares of Iradimed stock. The shares were sold at an average price of $22.83, for a total transaction of $114,150.00.
  • On Wednesday, July 31st, Brent Johnson sold 8,000 shares of Iradimed stock. The shares were sold at an average price of $22.68, for a total transaction of $181,440.00.
  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.46, for a total transaction of $20,460.00.
  • On Wednesday, July 3rd, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $20.16, for a total transaction of $60,480.00.
  • On Friday, June 28th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $20.53, for a total transaction of $41,060.00.
  • On Wednesday, June 26th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.34, for a total transaction of $20,340.00.

Shares of IRMD stock traded down $0.67 during trading hours on Thursday, hitting $20.31. 791 shares of the company’s stock were exchanged, compared to its average volume of 108,068. The stock has a market capitalization of $235.93 million, a P/E ratio of 48.26 and a beta of 1.65. Iradimed Corp has a 12-month low of $16.68 and a 12-month high of $38.78. The stock has a 50 day simple moving average of $19.95. The company has a quick ratio of 9.39, a current ratio of 10.29 and a debt-to-equity ratio of 0.06.

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Bank of New York Mellon Corp raised its position in Iradimed by 8.1% in the 4th quarter. Bank of New York Mellon Corp now owns 33,252 shares of the medical equipment provider’s stock worth $813,000 after buying an additional 2,503 shares during the last quarter. Geode Capital Management LLC raised its position in Iradimed by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 45,822 shares of the medical equipment provider’s stock worth $1,120,000 after buying an additional 1,690 shares during the last quarter. Bank of America Corp DE raised its position in Iradimed by 24.8% in the 4th quarter. Bank of America Corp DE now owns 19,532 shares of the medical equipment provider’s stock worth $477,000 after buying an additional 3,882 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in Iradimed in the 1st quarter worth about $76,000. Finally, Victory Capital Management Inc. purchased a new position in Iradimed in the 1st quarter worth about $212,000. 23.49% of the stock is currently owned by institutional investors.

IRMD has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. ValuEngine raised shares of Iradimed from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, Zacks Investment Research downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $31.50.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Recommended Story: Special Dividends

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.